AgingResearch.NewsJoin free

PD-L1 nanomodulator

PD-L1 nanomodulator has been studied in 1 paper since 2025: none in people yet, 1 in animals. The research so far is in animals. The newest paper, May 19, 2025: “Spatially Targeted PD-L1 Blockade for Restoring Exhausted Cytotoxic T Lymphocyte Rejuvenation to Potentiate Multimodal-Immune Synergistic Therapies for Breast Cancer Treatment”.

Intervention

1 paper studies it2 findingsUpdated

None of its findings points the other way.

C, W, M, H: cells, worms or flies, mice, humans. Dark: independent labs found the same change there. Light: one lab or one study. Outline: nothing yet.

  • 1 lab in 1 country
  • Funder: National Natural Science Foundation of China
  • Animals1

What did studies of PD-L1 nanomodulator find?

2

Studies of PD-L1 nanomodulator measured 2 outcomes; the most studied are immune response (1 study) and breast cancer (1).

Immune response

upin animals1

1 study

  1. PD-L1 nanomodulator activates immune response.

    “Both in vitro and in vivo studies confirm the nanomodulator can significantly amplify antitumor immune responses”

    Animals

    Spatially Targeted PD-L1 Blockade for Restoring Exhausted Cytotoxic T Lymphocyte Rejuvenation to Potentiate Multimodal-Immune Synergistic Therapies for Breast Cancer Treatment

    Small (Weinheim an der Bergstrasse, Germany)

More on Immune response

Breast cancer

downin animals1

1 study

  1. PD-L1 nanomodulator decreases breast cancer.

    “eventually lead to substantial inhibition of tumor growth, metastasis, and recurrence.”

    Animals

    Spatially Targeted PD-L1 Blockade for Restoring Exhausted Cytotoxic T Lymphocyte Rejuvenation to Potentiate Multimodal-Immune Synergistic Therapies for Breast Cancer Treatment

    Small (Weinheim an der Bergstrasse, Germany)

More on Breast cancer

Latest

Related